Literature DB >> 35503494

Serum hormone levels and normal breast histology among premenopausal women.

Mark E Sherman1, Thomas de Bel2,3, Michael G Heckman4, Launia J White4, Joshua Ogony4, Melody Stallings-Mann5, Tracy Hilton4, Amy C Degnim6, Robert A Vierkant7, Tanya Hoskin7, Matthew R Jensen7, Laura Pacheco-Spann4, Jill E Henry8, Anna Maria Storniolo8, Jodi M Carter9, Stacey J Winham7, Derek C Radisky5, Jeroen van der Laak2,3,10.   

Abstract

PURPOSE: Breast terminal duct lobular units (TDLUs) are the main source of breast cancer (BC) precursors. Higher serum concentrations of hormones and growth factors have been linked to increased TDLU numbers and to elevated BC risk, with variable effects by menopausal status. We assessed associations of circulating factors with breast histology among premenopausal women using artificial intelligence (AI) and preliminarily tested whether parity modifies associations.
METHODS: Pathology AI analysis was performed on 316 digital images of H&E-stained sections of normal breast tissues from Komen Tissue Bank donors ages ≤ 45 years to assess 11 quantitative metrics. Associations of circulating factors with AI metrics were assessed using regression analyses, with inclusion of interaction terms to assess effect modification.
RESULTS: Higher prolactin levels were related to larger TDLU area (p < 0.001) and increased presence of adipose tissue proximate to TDLUs (p < 0.001), with less significant positive associations for acini counts (p = 0.012), dilated acini (p = 0.043), capillary area (p = 0.014), epithelial area (p = 0.007), and mononuclear cell counts (p = 0.017). Testosterone levels were associated with increased TDLU counts (p < 0.001), irrespective of parity, but associations differed by adipose tissue content. AI data for TDLU counts generally agreed with prior visual assessments.
CONCLUSION: Among premenopausal women, serum hormone levels linked to BC risk were also associated with quantitative features of normal breast tissue. These relationships were suggestively modified by parity status and tissue composition. We conclude that the microanatomic features of normal breast tissue may represent a marker of BC risk.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Breast cancer risk; Hormones; Normal breast tissue; Terminal duct lobular units

Mesh:

Substances:

Year:  2022        PMID: 35503494     DOI: 10.1007/s10549-022-06600-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.624


  35 in total

1.  Age-related lobular involution and risk of breast cancer.

Authors:  Tia R Milanese; Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Amy C Degnim; Celine M Vachon; Carol A Reynolds; Romayne A Thompson; L Joseph Melton; Ellen L Goode; Daniel W Visscher
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

2.  An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions.

Authors:  S R Wellings; H M Jensen; R G Marcum
Journal:  J Natl Cancer Inst       Date:  1975-08       Impact factor: 13.506

3.  Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study.

Authors:  Jonine D Figueroa; Ruth M Pfeiffer; Louise A Brinton; Maya M Palakal; Amy C Degnim; Derek Radisky; Lynn C Hartmann; Marlene H Frost; Melody L Stallings Mann; Daphne Papathomas; Gretchen L Gierach; Stephen M Hewitt; Maire A Duggan; Daniel Visscher; Mark E Sherman
Journal:  Breast Cancer Res Treat       Date:  2016-08-03       Impact factor: 4.872

4.  Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression.

Authors:  Holly A Martinson; Sonali Jindal; Clarissa Durand-Rougely; Virginia F Borges; Pepper Schedin
Journal:  Int J Cancer       Date:  2014-09-15       Impact factor: 7.396

5.  Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology.

Authors:  Jonine D Figueroa; Ruth M Pfeiffer; Deesha A Patel; Laura Linville; Louise A Brinton; Gretchen L Gierach; Xiaohong R Yang; Daphne Papathomas; Daniel Visscher; Carolyn Mies; Amy C Degnim; William F Anderson; Stephen Hewitt; Zeina G Khodr; Susan E Clare; Anna Maria Storniolo; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2014-10-01       Impact factor: 13.506

6.  Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.

Authors:  Traci R Lyons; Jenean O'Brien; Virginia F Borges; Matthew W Conklin; Patricia J Keely; Kevin W Eliceiri; Andriy Marusyk; Aik-Choon Tan; Pepper Schedin
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

Review 7.  Microenvironment of the involuting mammary gland mediates mammary cancer progression.

Authors:  Pepper Schedin; Jenean O'Brien; Michael Rudolph; Torsten Stein; Virginia Borges
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

8.  Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling.

Authors:  Sonali Jindal; Dexiang Gao; Pat Bell; Grethe Albrektsen; Susan M Edgerton; Christine B Ambrosone; Ann D Thor; Virginia F Borges; Pepper Schedin
Journal:  Breast Cancer Res       Date:  2014-03-28       Impact factor: 6.466

9.  Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms.

Authors:  Taylor R Wallace; Sarah E Tarullo; Lyndsey S Crump; Traci R Lyons
Journal:  J Cancer Metastasis Treat       Date:  2019-02-19

Review 10.  Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop.

Authors:  Jessica M Faupel-Badger; Kathleen F Arcaro; Jane J Balkam; A Heather Eliassen; Foteini Hassiotou; Carlito B Lebrilla; Karin B Michels; Julie R Palmer; Pepper Schedin; Alison M Stuebe; Christine J Watson; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.